Xamex

Xamex may be available in the countries listed below.

Ingredient matches for Xamex

Secnidazole

Secnidazole is reported as an ingredient of Xamex in the following countries:

• Ecuador

International Drug Name Search

Faspic

Faspic may be available in the countries listed below.

Ingredient matches for Faspic

Ibuprofen

Ibuprofen is reported as an ingredient of Faspic in the following countries:

• Romania

Ibuprofen arginine (a derivative of Ibuprofen) is reported as an ingredient of Faspic in the following countries:

• Thailand

International Drug Name Search

Cytospaz

Ingredient matches for Cytospaz

Hyoscyamine

Hyoscyamine is reported as an ingredient of Cytospaz in the following countries:

• United States

International Drug Name Search

Flumil

Flumil may be available in the countries listed below.

Ingredient matches for Flumil

Acetylcysteine

Acetylcysteine is reported as an ingredient of Flumil in the following countries:

• Spain

Fluconazole

Fluconazole is reported as an ingredient of Flumil in the following countries:

• Peru

International Drug Name Search

Pentastar

Pentastar may be available in the countries listed below.

Ingredient matches for Pentastar

Pantoprazole

Pantoprazole is reported as an ingredient of Pentastar in the following countries:

• India

International Drug Name Search

Alben

Alben may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Alben

Albendazole

Albendazole is reported as an ingredient of Alben in the following countries:

• Australia


• Bangladesh


• Peru

International Drug Name Search

Aescephaline

Aescephaline may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Aescephaline

Cefalexin

Cefalexin monohydrate (a derivative of Cefalexin) is reported as an ingredient of Aescephaline in the following countries:

• Netherlands

International Drug Name Search

Glucoton

Glucoton may be available in the countries listed below.

Ingredient matches for Glucoton

Gliclazide

Gliclazide is reported as an ingredient of Glucoton in the following countries:

• Georgia

International Drug Name Search

Ilduc

Ilduc may be available in the countries listed below.

Ingredient matches for Ilduc

Amlodipine

Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Ilduc in the following countries:

• Argentina

International Drug Name Search

Ridrase

Ridrase may be available in the countries listed below.

Ingredient matches for Ridrase

Probucol

Probucol is reported as an ingredient of Ridrase in the following countries:

• Japan

International Drug Name Search

Ketobifan

Ketobifan may be available in the countries listed below.

Ingredient matches for Ketobifan

Ketoconazole

Ketoconazole is reported as an ingredient of Ketobifan in the following countries:

• Colombia

International Drug Name Search

Micafungin Sodium

Micafungin Sodium may be available in the countries listed below.

Ingredient matches for Micafungin Sodium

Micafungin

Micafungin Sodium (USAN) is known as Micafungin in the US.

International Drug Name Search

Glossary

USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Cardilopin

Cardilopin may be available in the countries listed below.

Ingredient matches for Cardilopin

Amlodipine

Amlodipine is reported as an ingredient of Cardilopin in the following countries:

• Vietnam

Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Cardilopin in the following countries:

• Czech Republic


• Georgia


• Hungary


• Poland


• Russian Federation


• Slovakia

International Drug Name Search

Matcine

Matcine may be available in the countries listed below.

Ingredient matches for Matcine

Chlorpromazine

Chlorpromazine hydrochloride (a derivative of Chlorpromazine) is reported as an ingredient of Matcine in the following countries:

• Myanmar


• Singapore

International Drug Name Search

Xusal

Xusal may be available in the countries listed below.

Ingredient matches for Xusal

Levocetirizine

Levocetirizine dihydrochloride (a derivative of Levocetirizine) is reported as an ingredient of Xusal in the following countries:

• Germany

International Drug Name Search

Rebetol Oral Solution

1. Name Of The Medicinal Product

Rebetol 40 mg/ml oral solution

2. Qualitative And Quantitative Composition

Each ml of oral solution contains 40 mg of ribavirin.

Rebetol contains 142 mg of sorbitol and 300 mg of sucrose per ml.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Oral solution

Clear, colourless to pale or light yellow oral solution

4. Clinical Particulars

4.1 Therapeutic Indications

Rebetol is indicated, in a combination regimen with peginterferon alfa-2b or interferon alfa-2b, for the treatment of children 3 years of age and older and adolescents, who have chronic hepatitis C virus (HCV) infection, not previously treated, without liver decompensation, and who are positive for hepatitis C viral ribonucleic acid (HCV-RNA).

When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis (see section 4.4).

Rebetol monotherapy must not be used.

There is no safety or efficacy information in children or adolescents on the use of Rebetol with other forms of interferon (i.e., not alfa-2b).

4.2 Posology And Method Of Administration

Treatment should be initiated, and monitored, by a physician experienced in the management of chronic hepatitis C.

Please refer also to the pegylated interferon alfa-2b or interferon alfa-2b Summary of Product Characteristics (SPC) for prescribing information particular to that product.

Dose to be administered

Rebetol oral solution is supplied in a concentration of 40 mg/ml.

Children 3 years of age and older and adolescents:

Rebetol oral solution is administered orally in two divided doses (morning and evening) with food

Dosing for children and adolescent patients is determined by body weight for Rebetol and by body surface area for peginterferon alfa-2b and interferon alfa-2b.

The recommended dose of peginterferon alfa-2b is 60 µg/m²/week subcutaneously in combination with Rebetol 15 mg/kg/day (Table 1).

In clinical studies performed in this population, ribavirin and interferon alfa-2b were used in doses of 15 mg/kg/day (Table 1) and 3 million international units (MIU)/m² three times a week, respectively.

Table 1 Rebetol oral solution - Children and adolescents dosage
Body Weight (kg)	Measured Dose (Morning / Evening)
10-12	2 ml / 2 ml
13-14	3 ml / 2 ml
15-17	3 ml / 3 ml
18-20	4 ml / 3 ml
21-22	4 ml / 4 ml
23-25	5 ml / 4 ml
26-28	5 ml / 5 ml
29-31	6 ml / 5 ml
32-33	6 ml / 6 ml
34-36	7 ml / 6 ml
37-39	7 ml / 7 ml
40-41	8 ml / 7 ml
42-44	8 ml / 8 ml
45-47	9 ml / 8 ml

Patients who weigh > 47 kg and are able to swallow capsules may take the equivalent dose of ribavirin 200 mg capsules in two divided doses (Please see SPC for ribavirin capsules).

Duration of treatment

• Genotype 1. The recommended duration of treatment is one year. By extrapolation from clinical data on combination therapy with standard interferon in paediatric patients (negative predictive value 96 % for interferon alfa-2b/Rebetol), patients who fail to achieve virological response at 12 weeks are highly unlikely to become sustained virological responders. Therefore, it is recommended that children and adolescent patients receiving interferon alfa-2b (pegylated and non-pegylated)/Rebetol combination be discontinued from therapy if their week 12 HCV-RNA dropped < 2 log₁₀ compared to pretreatment, or if they have detectable HCV-RNA at treatment week 24.

• Genotype 2 or 3: The recommended duration of treatment is 24 weeks.

• Genotype 4: Only 5 children and adolescents with Genotype 4 were treated in the peginterferon alfa-2b/Rebetol clinical trial. The recommended duration of treatment is 1 year. It is recommended that children and adolescent patients receiving peginterferon alfa-2b/Rebetol combination be discontinued from therapy if their week 12 HCV-RNA dropped < 2 log₁₀ compared to pretreatment, or if they have detectable HCV-RNA at treatment week 24.

Dose modification

If severe adverse reactions or laboratory abnormalities develop during therapy with Rebetol oral solution and interferon alfa-2b, modify the dosages of each product if appropriate, until the adverse reactions abate. Guidelines were developed in clinical trials for dose modification (see Dosage modification guidelines, Table 2). As adherence might be of importance for outcome of therapy, the dose should be kept as close as possible to the recommended standard dose. The potential negative impact of ribavirin dose reduction on efficacy results could not be ruled out.

Table 2. Dosage modification guidelines for children and adolescents based on laboratory parameters
Laboratory values	Reduce only Rebetol dose (see note 1) if:	Reduce only peginterferon alfa-2b or interferon alfa-2b dose (see note 2) if:	Discontinue combination therapy when the below test value is reported: **
Haemoglobin	< 10 g/dl	-	< 8.5 g/dl
Leukocytes	-	< 1.5 x 109/l	< 1.0 x 109/l
Neutrophils	-	< 0.75 x 109/l	< 0.5 x 109/l
Platelets	-	< 70 x 109/l	< 50 x 109/l
Bilirubin – Direct	-	-	2.5 x ULN*
Bilirubin – Indirect	> 5 mg/dl	-	> 5 mg/dl (for > 4 weeks) treated with interferon alfa-2b), or > 4 mg/dl (for > 4 weeks treated with peginterferon alfa-2b)
Serum Creatinine	-	-	> 2.0 mg/dl
Creatinine Clearance			Discontinue Rebetol if CrCl < 50 ml/minute
Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST)	-	-	2 x baseline and > 10 x ULN* or 2 x baseline and > 10 x ULN*

^* Upper limit of normal

^** Refer to the SPC for pegylated interferon alfa-2b and interferon alfa-2b for dose modification and discontinuation.

Note 1: In children and adolescent patients treated with Rebetol plus peginterferon alfa-2b, 1st dose reduction of Rebetol is to 12 mg/kg/day, 2nd dose reduction of Rebetol is to 8 mg/kg/day.

In children and adolescent patients treated with Rebetol plus interferon alfa-2b, reduce Rebetol dose to 7.5 mg/kg/day.

Note 2: In children and adolescent patients treated with Rebetol plus peginterferon alfa-2b, 1st dose reduction of peginterferon alfa-2b is to 40 µg/m2/week, 2nd dose reduction of peginterferon alfa-2b is to 20 µg/m2/week.

In children and adolescent patients treated with Rebetol plus interferon alfa-2b, reduce the interferon alfa-2b dose by one-half dose.

Special populations

Use in renal impairment: The pharmacokinetics of ribavirin are altered in patients with renal dysfunction due to reduction of apparent creatinine clearance in these patients (see section 5.2). Therefore, it is recommended that renal function be evaluated in all patients prior to initiation of Rebetol. Patients with creatinine clearance < 50 ml/minute must not be treated with Rebetol (see section 4.3). Subjects with impaired renal function should be more carefully monitored with respect to the development of anaemia. If serum creatinine rises to > 2.0 mg/dl (see Table 2), Rebetol and interferon alfa-2b must be discontinued.

Use in hepatic impairment: No pharmacokinetic interaction appears between ribavirin and hepatic function (see section 5.2). Therefore, no dose adjustment of Rebetol is required in patients with hepatic impairment. The use of ribavirin is contraindicated in patients with severe hepatic impairment or decompensated cirrhosis (see section 4.3).

Use in patients under the age of 18 years: Rebetol may be used in combination with peginterferon alfa-2b or interferon alfa-2b in children 3 years of age and older and adolescents. The selection of formulation is based on individual characteristics of the patient. Safety and effectiveness of Rebetol with other forms of interferon (i.e. not alfa-2b) in these patients have not been evaluated.

Patients co-infected with HCV/HIV: Patients taking nucleoside reverse transcriptase inhibitor (NRTI) treatment in association with ribavirin and interferon alfa-2b or peginterferon alfa-2b may be at increased risk of mitochondrial toxicity, lactic acidosis and hepatic decompensation (see section 4.4). Please refer also to the relevant product information for antiretroviral medicinal products.

4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients.

- Pregnant women (see sections 4.4, 4.6 and 5.3). In females of childbearing potential, Rebetol must not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy.

- Lactation.

- A history of severe pre-existing cardiac disease, including unstable or uncontrolled cardiac disease, in the previous six months (see section 4.4).

- Patients with severe, debilitating medical conditions.

- Patients with chronic renal failure, patients with creatinine clearance < 50 ml/minute and/or on haemodialysis.

- Severe hepatic impairment (Child-Pugh Classification B or C) or decompensated cirrhosis of the liver.

- Haemoglobinopathies (e.g., thalassemia, sickle-cell anaemia).

Children and adolescents:

- Existence of, or history of severe psychiatric condition, particularly severe depression, suicidal ideation, or suicide attempt.

Because of co-administration with peginterferon alfa-2b or interferon alfa-2b:

- Autoimmune hepatitis; or history of autoimmune disease.

4.4 Special Warnings And Precautions For Use

Psychiatric and Central Nervous System (CNS): Severe CNS effects, particularly depression, suicidal ideation and attempted suicide have been observed in some patients during Rebetol combination therapy with peginterferon alfa-2b or interferon alfa-2b, and even after treatment discontinuation mainly during the 6-month follow-up period. Among children and adolescents, treated with Rebetol in combination with interferon alfa-2b, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4 % versus 1 %) during treatment and during the 6-month follow-up after treatment. As in adult patients, children and adolescents experienced other psychiatric adverse reactions (e.g., depression, emotional lability, and somnolence). Other CNS effects including aggressive behaviour (sometimes directed against others such as homicidal ideation), bipolar disorder, mania, confusion and alterations of mental status have been observed with alpha interferons. Patients should be closely monitored for any signs or symptoms of psychiatric disorders. If such symptoms appear, the potential seriousness of these undesirable effects must be borne in mind by the prescribing physician and the need for adequate therapeutic management should be considered. If psychiatric symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Rebetol and peginterferon alfa-2b or interferon alfa-2b be discontinued, and the patient followed, with psychiatric intervention as appropriate. Patients with existence of or history of severe psychiatric conditions: The use of Rebetol and interferon alfa-2b or peginterferon alfa-2b in children and adolescents with existence of or history of severe psychiatric conditions is contraindicated (see section 4.3). Patients with substance use/abuse: HCV infected patients having a co-occurring substance use disorder (alcohol, cannabis, etc) are at an increased risk of developing psychiatric disorders or exacerbation of already existing psychiatric disorders when treated with alpha interferon. If treatment with alpha interferon is judged necessary in these patients, the presence of psychiatric co-morbidities and the potential for other substance use should be carefully assessed and adequately managed before initiating therapy. If necessary, an inter-disciplinary approach including a mental health care provider or addiction specialist should be considered to evaluate, treat and follow the patient. Patients should be closely monitored during therapy and even after treatment discontinuation. Early intervention for re-emergence or development of psychiatric disorders and substance use is recommended.

Growth and development (children and adolescents): During the course of interferon (standard and pegylated)/ribavirin therapy lasting up to 48 weeks in patients ages 3 through 17 years, weight loss and growth inhibition were common (see sections 4.8 and 5.1). The longer term data available in children treated with the combination therapy with standard interferon/ribavirin are also indicative of substantial growth retardation (>15 percentile decrease in height percentile as compared to baseline) in 21 % of children despite being off treatment for more than 5 years. Case by case benefit/risk assessment in children: The expected benefit of treatment should be carefully weighed against the safety findings observed for children and adolescents in the clinical trials (see sections 4.8 and 5.1). −       It is important to consider that the combination therapy induced a growth inhibition, the reversibility of which is uncertain. −       This risk should be weighed against the disease characteristics of the child, such as evidence of disease progression (notably fibrosis), co-morbidities that may negatively influence the disease progression (such as HIV-co-infection), as well as prognostic factors of response (HCV genotype and viral load). Whenever possible the child should be treated after the pubertal growth spurt, in order to reduce the risk of growth inhibition. There are no data on long term effects on sexual maturation.

Based on results of clinical trials, the use of ribavirin as monotherapy is not effective and Rebetol must not be used alone. The safety and efficacy of this combination have been established only using ribavirin together with peginterferon alfa-2b or with interferon alfa-2b solution for injection.

Haemolysis: A decrease in haemoglobin levels to < 10 g/dl was observed in up to 14 % of adult patients and in 7 % of children and adolescents treated with Rebetol in combination with peginterferon alfa-2b or interferon alfa-2b in clinical trials. Although ribavirin has no direct cardiovascular effects, anaemia associated with Rebetol may result in deterioration of cardiac function, or exacerbation of the symptoms of coronary disease or both. Thus, Rebetol must be administered with caution to patients with pre-existing cardiac disease (see section 4.3). Cardiac status must be assessed before start of therapy and monitored clinically during therapy; if any deterioration occurs, therapy must be stopped (see section 4.2).

Cardiovascular: Adult patients with a history of congestive heart failure, myocardial infarction and/or previous or current arrhythmic disorders must be closely monitored. It is recommended that those patients who have pre-existing cardiac abnormalities have electrocardiograms taken prior to and during the course of treatment. Cardiac arrhythmias (primarily supraventricular) usually respond to conventional therapy but may require discontinuation of therapy. There are no data in children and adolescents with a history of cardiac disease.

Acute hypersensitivity: If an acute hypersensitivity reaction (e.g., urticaria, angioedema, bronchoconstriction, anaphylaxis) develops, Rebetol must be discontinued immediately and appropriate medical therapy instituted. Transient rashes do not necessitate interruption of treatment.

Ocular changes: Ribavirin is used in combination therapy with alpha interferons. Retinopathy including retinal haemorrhages, retinal exudates, papilloedema, optic neuropathy and retinal artery or vein occlusion which may result in loss of vision have been reported in rare instances with combination therapy with alpha interferons. All patients should have a baseline eye examination. Any patient complaining of decrease or loss of vision must have a prompt and complete eye examination. Patients with preexisting ophthalmologic disorders (e.g., diabetic or hypertensive retinopathy) should receive periodic ophthalmologic exams during combination therapy with alpha interferons. Combination therapy with alpha interferons should be discontinued in patients who develop new or worsening ophthalmologic disorders.

Liver function: Any patient developing significant liver function abnormalities during treatment must be monitored closely. Discontinue treatment in patients who develop prolongation of coagulation markers which might indicate liver decompensation.

Potential to exacerbate immunosuppression: Pancytopenia and bone marrow suppression have been reported in the literature to occur within 3 to 7 weeks after the administration of a peginterferon and ribavirin concomitantly with azathioprine. This myelotoxicity was reversible within 4 to 6 weeks upon withdrawal of HCV antiviral therapy and concomitant azathioprine and did not recur upon reintroduction of either treatment alone (see section 4.5).

Thyroid supplemental monitoring for children and adolescents:

Approximately 12 to 21 % of children treated with Rebetol and interferon alfa-2b (pegylated and non-pegylated) developed increase in thyroid stimulating hormone (TSH). Another approximately 4 % had a transient decrease below the lower limit of normal. Prior to initiation of interferon alfa-2b therapy, TSH levels must be evaluated and any thyroid abnormality detected at that time must be treated with conventional therapy. Interferon alfa-2b (pegylated and non-pegylated) therapy may be initiated if TSH levels can be maintained in the normal range by medication. Thyroid dysfunction during treatment with Rebetol and interferon alfa-2b and during treatment with Rebetol and peginterferon alfa-2b has been observed. If thyroid abnormalities are detected, the patient's thyroid status should be evaluated and treated as clinically appropriate. Children and adolescents patients should be monitored every 3 months for evidence of thyroid dysfunction (e.g. TSH).

HCV/HIV Co-infection:

Mitochondrial toxicity and lactic acidosis:

Caution should be taken in HIV-positive subjects co-infected with HCV who receive nucleoside reverse transcriptase inhibitor (NRTI) treatment (especially ddI and d4T) and associated interferon alfa-2b/ribavirin treatment. In the HIV-positive population receiving an NRTI regimen, physicians should carefully monitor markers of mitochondrial toxicity and lactic acidosis when ribavirin is administered. In particular:

- co-administration of Rebetol and didanosine is not recommended due to the risk of mitochondrial toxicity (see section 4.5).

- co-administration of Rebetol and stavudine should be avoided to limit the risk of overlapping mitochondrial toxicity.

Hepatic decompensation in HCV/HIV co-infected patients with advanced cirrhosis:

Co-infected patients with advanced cirrhosis receiving highly active anti-retroviral therapy (HAART) may be at increased risk of hepatic decompensation and death. Adding treatment with alfa interferons alone or in combination with ribavirin may increase the risk in this patient subset.

Haematological abnormalities in HCV/HIV co-infected patients:

Patients treated with ribavirin and zidovudine are at increased risk of developing anaemia; therefore, the concomitant use of ribavirin with zidovudine is not recommended (see section 4.5).

Dental and periodontal disorders: Dental and periodontal disorders, which may lead to loss of teeth, have been reported in patients receiving Rebetol and peginterferon alfa-2b or interferon alfa-2b combination therapy. In addition, dry mouth could have a damaging effect on teeth and mucous membranes of the mouth during long-term treatment with the combination of Rebetol and peginterferon alfa-2b or interferon alfa-2b. Patients should brush their teeth thoroughly twice daily and have regular dental examinations. In addition some patients may experience vomiting. If this reaction occurs, they should be advised to rinse out their mouth thoroughly afterwards.

Laboratory tests: Standard haematological tests and blood chemistries (complete blood count [CBC] and differential, platelet count, electrolytes, serum creatinine, liver function tests, uric acid) must be conducted in all patients prior to initiating therapy. Acceptable baseline values that may be considered as a guideline prior to initiation of Rebetol therapy in children and adolescents:

Haemoglobin
Platelets	3
Neutrophil Count	3

Laboratory evaluations are to be conducted at weeks 2 and 4 of therapy, and periodically thereafter as clinically appropriate. HCV-RNA should be measured periodically during treatment (see section 4.2).

For females of childbearing potential: Female patients must have a routine pregnancy test performed monthly during treatment and for four months thereafter. Female partners of male patients must have a routine pregnancy test performed monthly during treatment and for seven months thereafter (see section 4.6).

Uric acid may increase with Rebetol due to haemolysis; therefore, the potential for development of gout must be carefully monitored in pre-disposed patients.

Use in patients with rare hereditary disorders: This product contains sucrose and sorbitol. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption syndrome or sucrase-isomaltase insufficiency should not take this medicine.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

Results of in vitro studies using both human and rat liver microsome preparations indicated no cytochrome P450 enzyme mediated metabolism of ribavirin. Ribavirin does not inhibit cytochrome P450 enzymes. There is no evidence from toxicity studies that ribavirin induces liver enzymes. Therefore, there is a minimal potential for P450 enzyme-based interactions.

Ribavirin, by having an inhibitory effect on inosine monophosphate dehydrogenase, may interfere with azathioprine metabolism possibly leading to an accumulation of 6-methylthioinosine monophosphate (6-MTIMP), which has been associated with myelotoxicity in patients treated with azathioprine. The use of pegylated alpha interferons and ribavirin concomitantly with azathioprine should be avoided. In individual cases where the benefit of administering ribavirin concomitantly with azathioprine warrants the potential risk, it is recommended that close hematologic monitoring be done during concomitant azathioprine use to identify signs of myelotoxicity, at which time treatment with these medicines should be stopped (see section 4.4).

No interaction studies have been conducted with Rebetol and other medicinal products, except for interferon alfa-2b and antacids.

Interferon alfa-2b: No pharmacokinetic interactions were noted between Rebetol and interferon alfa-2b in a multiple-dose pharmacokinetic study.

Antacid: The bioavailability of ribavirin 600 mg was decreased by co-administration with an antacid containing magnesium, aluminium and simethicone; AUC_tf decreased 14 %. It is possible that the decreased bioavailability in this study was due to delayed transit of ribavirin or modified pH. This interaction is not considered to be clinically relevant.

Nucleoside analogues: Use of nucleoside analogs, alone or in combination with other nucleosides, has resulted in lactic acidosis. Pharmacologically, ribavirin increases phosphorylated metabolites of purine nucleosides in vitro. This activity could potentiate the risk of lactic acidosis induced by purine nucleoside analogs (e.g. didanosine or abacavir). Co-administration of Rebetol and didanosine is not recommended. Reports of mitochondrial toxicity, in particular lactic acidosis and pancreatitis, of which some fatal, have been reported (see section 4.4).

The exacerbation of anaemia due to ribavirin has been reported when zidovudine is part of the regimen used to treat HIV although the exact mechanism remains to be elucidated. The concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia (see section 4.4). Consideration should be given to replacing zidovudine in a combination anti-retroviral treatment (ART) regimen if this is already established. This would be particularly important in patients with a known history of zidovudine induced anaemia.

Any potential for interactions may persist for up to two months (five half-lives for ribavirin) after cessation of Rebetol therapy due to the long half-life (see section 5.2).

There is no evidence that ribavirin interacts with non-nucleoside reverse transcriptase inhibitors or protease inhibitors.

4.6 Pregnancy And Lactation

The use of Rebetol is contraindicated during pregnancy.

Preclinical data:

- Fertility: In animal studies, ribavirin produced reversible effects on spermatogenesis (see section 5.3).

- Teratogenicity: Significant teratogenic and/or embryocidal potential have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted, occurring at doses as low as one twentieth of the recommended human dose (see section 5.3).

- Genotoxicity: Ribavirin induces genotoxicity (see section 5.3).

Female patients: Rebetol must not be used by females who are pregnant (see sections 4.3, and 5.3). Extreme care must be taken to avoid pregnancy in female patients (see section 5.3). Rebetol therapy must not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Females of childbearing potential and their partners must each use an effective contraceptive during treatment and for four months after treatment has been concluded; routine monthly pregnancy tests must be performed during this time. If pregnancy does occur during treatment or within four months from stopping treatment, the patient must be advised of the significant teratogenic risk of ribavirin to the foetus.

Male patients and their female partners: Extreme care must be taken to avoid pregnancy in partners of male patients taking Rebetol (see sections 4.3, and 5.3). Ribavirin accumulates intracellularly and is cleared from the body very slowly. It is unknown whether the ribavirin that is contained in sperm will exert its potential teratogenic or genotoxic effects on the human embryo/foetus. Although data on approximately 300 prospectively followed pregnancies with paternal exposure to ribavirin have not shown an increased risk of malformation compared to the general population, nor any specific pattern of malformation, male patients and their female partners of childbearing age must be advised to each use an effective contraceptive during treatment with Rebetol and for seven months after treatment. Men whose partners are pregnant must be instructed to use a condom to minimise delivery of ribavirin to the partner.

Breast-feeding: It is not known whether ribavirin is excreted in human milk. Because of the potential for adverse reactions in breast-fed infants, breast-feeding must be discontinued prior to initiation of treatment.

4.7 Effects On Ability To Drive And Use Machines

Rebetol has no or negligible influence on the ability to drive or use machines; however, interferon alfa-2b used in combination may have an effect. Thus, patients who develop fatigue, somnolence, or confusion during treatment must be cautioned to avoid driving or operating machinery.

4.8 Undesirable Effects

Children and adolescents:

In combination with peginterferon alfa-2b

In a clinical trial with 107 children and adolescent patients (3 to 17 years of age) treated with combination therapy of peginterferon alfa-2b and Rebetol, dose modifications were required in 25 % of patients, most commonly for anaemia, neutropenia and weight loss. In general, the adverse reactions profile in children and adolescents was similar to that observed in adults, although there is a paediatric-specific concern regarding growth inhibition. During combination therapy for up to 48 weeks with pegylated interferon alfa-2b and Rebetol, growth inhibition is observed, the reversibility of which is uncertain (see section 4.4). Weight loss and growth inhibition were very common during the treatment (at the end of treatment, mean decrease from baseline in weight and in height percentiles were of 15 percentiles and 8 percentiles, respectively) and growth velocity was inhibited (< 3^rd percentile in 70 % of the patients).

At the end of 24 weeks post-treatment follow-up, mean decrease from baseline in weight and height percentiles were still of 3 percentiles and 7 percentiles, respectively, and 20 % of the children continued to have inhibited growth (growth velocity < 3^rd percentile). Based on interim data from the long-term follow-up portion of this study, 22 % (16/74) of children had a > 15 percentile decrease in height percentile, of whom 3 (4 %) children had a > 30 percentile decrease despite being off treatment for more than 1 year. In particular, decrease in mean height percentile at year 1 of long-term follow-up was most prominent in prepubertal age children (see section 4.4).

In this study, the most prevalent adverse reactions in all subjects were pyrexia (80 %), headache (62 %), neutropenia (33 %), fatigue (30 %), anorexia (29 %) and injection site erythema (29 %). Only 1 subject discontinued therapy as the result of an adverse reaction (thrombocytopenia). The majority of adverse reactions reported in the study were mild or moderate in severity. Severe adverse reactions were reported in 7 % (8/107) of all subjects and included injection site pain (1 %), pain in extremity (1 %), headache (1 %), neutropenia (1 %), and pyrexia (4 %). Important treatment-emergent adverse reactions that occurred in this patient population were nervousness (8 %), aggression (3 %), anger (2 %), depression/depressed mood (4 %) and hypothyroidism (3 %) and 5 subjects received levothyroxine treatment for hypothyroidism/elevated TSH.

In combination with interferon alfa-2b

In clinical trials of 118 children and adolescents 3 to 16 years of age treated with combination therapy of interferon alfa-2b and Rebetol, 6 % discontinued therapy due to adverse reactions. In general, the adverse reaction profile in the limited children and adolescent population studied was similar to that observed in adults, although there is a paediatric-specific concern regarding growth inhibition as decrease in height percentile (mean percentile decrease of 9 percentile) and weight percentile (mean percentile decrease of 13 percentile) were observed during treatment. Within the 5 years follow-up post-treatment period, the children had a mean height of 44^th percentile, which was below the median of the normative population and less than their mean baseline height (48^th percentile). Twenty (21 %) of 97 children had a> 15 percentile decrease in height percentile, of whom 10 of the 20 children had a> 30 percentile decrease in their height percentile from the start of treatment to the end of long-term follow-up (up to 5 years). During combination therapy for up to 48 weeks with interferon alfa-2b and Rebetol, growth inhibition is observed, the reversibility of which is uncertain. In particular, decrease in mean height percentile from baseline to the end of the long-term follow-up was most prominent in prepubertal age children (see section 4.4).

Furthermore, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4 % vs. 1 %) during treatment and during the 6 month follow-up after treatment. As in adult patients, children and adolescents also experienced other psychiatric adverse reactions (e.g., depression, emotional lability, and somnolence) (see section 4.4). In addition, injection site disorders, pyrexia, anorexia, vomiting and emotional lability occurred more frequently in children and adolescents compared to adult patients. Dose modifications were required in 30 % of patients, most commonly for anaemia and neutropenia.

Reported adverse reactions listed in Table 3 are based on experience from the two multicentre children and adolescents clinical trials using Rebetol with interferon alfa-2b or peginterferon alfa-2b. Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (

Table 3 Adverse reactions very commonly, commonly and uncommonly reported during clinical trials in children and adolescents with Rebetol in combination with interferon alfa-2b or peginterferon alfa-2b
System Organ Class	Adverse Reactions
Infections and infestations
Very common:	Viral infection, pharyngitis
Common:	Fungal infection, bacterial infection, pulmonary infection, nasopharyngitis, pharyngitis streptococcal, otitis media, sinusitis, tooth abscess, influenza, oral herpes, herpes simplex, urinary tract infection, vaginitis, gastroenteritis
Uncommon:	Pneumonia, ascariasis, enterobiasis, herpes zoster, cellulitis
Neoplasms benign, malignant and unspecified (including cysts and polyps)
Common:	Neoplasm unspecified
Blood and lymphatic system disorders
Very common:	Anaemia, neutropenia
Common:	Thrombocytopenia, lymphadenopathy
Endocrine disorders
Very common:	Hypothyroidism
Common:	Hyperthyroidism, virilism
Metabolism and nutrition disorders
Very common:	Anorexia, increased appetite, decreased appetite
Common:	Hypertriglyceridemia, hyperuricemia
Psychiatric disorders
Very common:	Depression, insomnia, emotional lability
Common:	Suicidal ideation, aggression, confusion, affect liability, behaviour disorder, agitation, somnambulism, anxiety, mood altered, restlessness, nervousness, sleep disorder, abnormal dreaming, apathy
Uncommon:	Abnormal behaviour, depressed mood, emotional disorder, fear, nightmare
Nervous system disorders

Paracof Roter

Paracof Roter may be available in the countries listed below.

Ingredient matches for Paracof Roter

Paracetamol

Paracetamol is reported as an ingredient of Paracof Roter in the following countries:

• Netherlands

International Drug Name Search

Amaday

Amaday may be available in the countries listed below.

Ingredient matches for Amaday

Amlodipine

Amlodipine is reported as an ingredient of Amaday in the following countries:

• Georgia

International Drug Name Search

Tromax

Tromax may be available in the countries listed below.

Ingredient matches for Tromax

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Tromax in the following countries:

• Ethiopia

International Drug Name Search

Palnac

Palnac may be available in the countries listed below.

Ingredient matches for Palnac

Tamsulosin

Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Palnac in the following countries:

• Japan

International Drug Name Search

Alfuzosin-CT

Alfuzosin-CT may be available in the countries listed below.

Ingredient matches for Alfuzosin-CT

Alfuzosin

Alfuzosin hydrochloride (a derivative of Alfuzosin) is reported as an ingredient of Alfuzosin-CT in the following countries:

• Germany

International Drug Name Search

Leuprorelin

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L02AE02

CAS registry number (Chemical Abstracts Service)

0053714-56-0

Chemical Formula

C59-H84-N16-O12

Molecular Weight

1209

Therapeutic Categories

Antineoplastic agent

Gonadotropin releasing hormone (GnRH) agonist

Chemical Name

Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide-

Foreign Names

• Leuprorelinum (Latin)
• Leuprorelin (German)
• Leuproréline (French)
• Leuprorelina (Spanish)

Generic Names

• Leuprorelin (OS: BAN)
• Leuprorelina (OS: DCIT)
• Leuproréline (OS: DCF)
• Leuprorelin (PH: BP 2010, Ph. Eur. 6)
• Leuproréline (PH: Ph. Eur. 6)
• Leuprorelinum (PH: Ph. Eur. 6)
• Leuprolide Acetate (OS: USAN)
• Leuprorelin Acetate (OS: BANM)
• A 43818 (IS)
• Abbott 43818 (IS)
• TAP 144 (IS)
• Leuprolide acetate (PH: USP 32)

Brand Names

• Enantone
  Takeda, France



• Leoprostin
  Chalver, Colombia



• Lorelina
  Palmagyar, Peru



• Tapros
  Takeda, Indonesia



• Acetato de Leuprolida Sandoz
  Sandoz, Colombia



• Daronda
  Abbott, Greece



• Depo Eligard
  Astellas, Belgium; Astellas Pharma S.A., Luxembourg



• Eligard
  Astellas, Austria; Astellas, Czech Republic; Astellas, Germany; Astellas, Denmark; Astellas, Estonia; Astellas, Spain; Astellas, Finland; Astellas, France; Astellas, Hungary; Astellas, Ireland; Astellas, Italy; Astellas, Lithuania; Astellas, Latvia; Astellas, Netherlands; Astellas, Norway; Astellas, Poland; Astellas, Portugal; Astellas, Slovenia; Astellas, Slovakia; Astellas Pharma, Switzerland; Astellas Pharma, Sweden; Hospira, Australia; Hospira, New Zealand; Medigene, Bulgaria; Novartis, Romania; Raffo, Argentina; sanofi-aventis, Canada; sanofi-aventis, United States; Tecnofarma, Colombia; Tolmar, United States; Veldos, Croatia (Hrvatska)



• Elityran
  Vianex / BIANEΞ, Greece



• Enanton Depot
  Orion, Finland; Orion, Norway



• Enanton Depot Dual
  Orion, Finland; Orion, Sweden



• Enanton Depot Set
  Orion, Sweden



• Enantone L.P.
  Takeda, Thailand



• Enantone
  Takeda, Austria; Takeda, Germany; Takeda, France; Takeda, Hong Kong; Takeda, Italy



• Enantone-Gyn
  Takeda, Austria; Takeda, Germany



• Endrolin
  Kalbe, Indonesia



• Eplerenone
  Abbott, United States



• Ginecrin
  Abbott Cientifica, Spain



• Gyno-Lucrin
  Abbott, Luxembourg



• Klebrocid
  Takeda, Germany



• Lectrum
  Novartis, Brazil; Sandoz, Argentina; Sandoz, Indonesia



• Leuplin Depot
  Takeda, Taiwan



• Leuplin
  Takeda, Japan



• Leuplin SR
  Takeda, Japan



• Leuprol
  Zapaco, Greece



• Leuprolide Acetate
  Bedford, United States; Genzyme, United States; Sun, United States; Takeda, Taiwan; Teva USA, United States



• Leuprone Hexal
  Hexal, Germany



• Leuprorelin Sandoz
  Sandoz, Switzerland



• Leupro-Sandoz
  Sandoz, Germany



• Lorelin
  Cryopharma, Mexico



• Lucrin Depot
  Abbott, Bosnia & Herzegowina; Abbott, Switzerland; Abbott, Czech Republic; Abbott, Hungary; Abbott, Israel; Abbott, Lithuania; Abbott, Mexico; Abbott, Netherlands; Abbott, New Zealand; Abbott, Portugal; Abbott, Romania; Abbott, Russian Federation; Abbott, South Africa; EU-Pharma, Netherlands; Euro, Netherlands; Medcor, Netherlands



• Lucrin
  Abbott, Australia; Abbott, Bosnia & Herzegowina; Abbott, Belgium; Abbott, Bulgaria; Abbott, Costa Rica; Abbott, Czech Republic; Abbott, Guatemala; Abbott, Honduras; Abbott, Luxembourg; Abbott, Malaysia; Abbott, Nicaragua; Abbott, Netherlands; Abbott, New Zealand; Abbott, Panama; Abbott, Poland; Abbott, Singapore; Abbott, Slovakia; Abbott, El Salvador; Abbott, Turkey; Abbott, South Africa; Takeda, Bulgaria



• Lupride
  Sun, India; Sun, Sri Lanka; Sun, Myanmar



• Luprolex
  Takeda, Philippines



• Lupron Vial Multidosis
  Abbott, Chile



• Lupron
  Abbott, Antigua & Barbuda; Abbott, Netherlands Antilles; Abbott, Argentina; Abbott, Aruba; Abbott, Barbados; Abbott, Bermuda; Abbott, Brazil; Abbott, Bahamas; Abbott, Chile; Abbott, Colombia; Abbott, Ecuador; Abbott, Grenada; Abbott, Guyana; Abbott, Haiti; Abbott, Jamaica; Abbott, Cayman Islands; Abbott, Saint Lucia; Abbott, Saint Lucia; Abbott, Oman; Abbott, Peru; Abbott, Suriname; Abbott, Turks & Caicos Islands; Abbott, Trinidad & Tobago; Abbott, United States; Abbott, Saint Vincent & The Grenadines; Abbott, Venezuela; Abbott, Virgin Islands (British); Takeda, Japan; TAP, Canada; TAP, United States



• Prametil
  Abbott, Luxembourg



• Prelar Depot
  Lemery, Mexico



• Procren
  Abbott, Finland; Abbott, Iceland



• Procren Depot
  Abbott, Denmark; Abbott, Iceland; Abbott, Norway; Abbott, Sweden



• Procrin
  Abbott, Spain



• Prostap
  AstraZeneca, Jordan; Takeda, United Kingdom; Wyeth, United Arab Emirates; Wyeth, Bahrain; Wyeth, Egypt; Wyeth, Ireland; Wyeth, Iraq; Wyeth, Iran; Wyeth, Kuwait; Wyeth, Lebanon; Wyeth, Oman; Wyeth, Qatar; Wyeth, Saudi Arabia; Wyeth, Syria; Wyeth, Yemen



• Prostide Depot
  Probiomed, Mexico



• Sixantone
  Takeda, Austria; Takeda, Germany



• Trenantone
  Takeda, Austria; Takeda, Germany



• Viadur
  Bayer, United States; Johnson & Johnson, United States

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Gelargin

Gelargin may be available in the countries listed below.

Ingredient matches for Gelargin

Fluocinolone

Fluocinolone Acetonide is reported as an ingredient of Gelargin in the following countries:

• Czech Republic


• Slovakia

International Drug Name Search

Antioxidans E-Hevert

Antioxidans E-Hevert may be available in the countries listed below.

Ingredient matches for Antioxidans E-Hevert

Tocopherol, α-

Tocopherol, α- acetate (a derivative of Tocopherol, α-) is reported as an ingredient of Antioxidans E-Hevert in the following countries:

• Germany

International Drug Name Search

Floxyfral

Floxyfral may be available in the countries listed below.

Ingredient matches for Floxyfral

Fluvoxamine

Fluvoxamine is reported as an ingredient of Floxyfral in the following countries:

• Tunisia

Fluvoxamine maleate (a derivative of Fluvoxamine) is reported as an ingredient of Floxyfral in the following countries:

• Austria


• Belgium


• France


• Luxembourg


• Switzerland

International Drug Name Search

Lincocine

Lincocine may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Lincocine

Lincomycin

Lincomycin is reported as an ingredient of Lincocine in the following countries:

• Tunisia

Lincomycin hydrochloride monohydrate (a derivative of Lincomycin) is reported as an ingredient of Lincocine in the following countries:

• Benin


• Burkina Faso


• Cameroon


• Central African Republic


• Chad


• Congo


• Cote D'ivoire


• France


• Gabon


• Guinea


• Madagascar


• Mali


• Mauritania


• Mauritius


• Niger


• Senegal


• Togo


• Zaire

Neomycin

Neomycin sulfate (a derivative of Neomycin) is reported as an ingredient of Lincocine in the following countries:

• France

International Drug Name Search

Apo-Amlo

Apo-Amlo may be available in the countries listed below.

Ingredient matches for Apo-Amlo

Amlodipine

Amlodipine is reported as an ingredient of Apo-Amlo in the following countries:

• Poland

Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Apo-Amlo in the following countries:

• Czech Republic

International Drug Name Search

Clorhidrato Dopamina Grifols

Clorhidrato Dopamina Grifols may be available in the countries listed below.

Ingredient matches for Clorhidrato Dopamina Grifols

Dopamine

Dopamine hydrochloride (a derivative of Dopamine) is reported as an ingredient of Clorhidrato Dopamina Grifols in the following countries:

• Spain

International Drug Name Search

Phenadoz

In the US, Phenadoz (promethazine systemic) is a member of the following drug classes: antihistamines, phenothiazine antiemetics and is used to treat Allergic Reactions, Anaphylaxis, Hay Fever, Light Sedation, Motion Sickness, Nausea/Vomiting, Opiate Adjunct, Sedation, Urticaria and Vertigo.

US matches:

• Phenadoz rectal


• Phenadoz

Ingredient matches for Phenadoz

Promethazine

Promethazine hydrochloride (a derivative of Promethazine) is reported as an ingredient of Phenadoz in the following countries:

• United States

International Drug Name Search

Mocloxil

Mocloxil may be available in the countries listed below.

Ingredient matches for Mocloxil

Moclobemide

Moclobemide is reported as an ingredient of Mocloxil in the following countries:

• Poland

International Drug Name Search

Ruibile

Ruibile may be available in the countries listed below.

Ingredient matches for Ruibile

Fluvoxamine

Fluvoxamine maleate (a derivative of Fluvoxamine) is reported as an ingredient of Ruibile in the following countries:

• China

International Drug Name Search

Caverta

Caverta may be available in the countries listed below.

Ingredient matches for Caverta

Sildenafil

Sildenafil citrate (a derivative of Sildenafil) is reported as an ingredient of Caverta in the following countries:

• Ecuador


• India


• Myanmar


• Peru


• Sri Lanka

International Drug Name Search

Monell

Monell may be available in the countries listed below.

Ingredient matches for Monell

Domperidone

Domperidone is reported as an ingredient of Monell in the following countries:

• Indonesia

International Drug Name Search

Pro-Famosal

Pro-Famosal may be available in the countries listed below.

Ingredient matches for Pro-Famosal

Famotidine

Famotidine is reported as an ingredient of Pro-Famosal in the following countries:

• Bosnia & Herzegowina


• Croatia (Hrvatska)

International Drug Name Search

Isocaine Hydrochloride with Levonordefrin

Ingredient matches for Isocaine Hydrochloride with Levonordefrin

Corbadrine

Corbadrine is reported as an ingredient of Isocaine Hydrochloride with Levonordefrin in the following countries:

• United States

Mepivacaine

Mepivacaine hydrochloride (a derivative of Mepivacaine) is reported as an ingredient of Isocaine Hydrochloride with Levonordefrin in the following countries:

• United States

International Drug Name Search

Isotretinoin Sandoz

Isotretinoin Sandoz may be available in the countries listed below.

Ingredient matches for Isotretinoin Sandoz

Isotretinoin

Isotretinoin is reported as an ingredient of Isotretinoin Sandoz in the following countries:

• Estonia


• Finland


• Latvia


• Switzerland

International Drug Name Search

Cidalin

Cidalin may be available in the countries listed below.

Ingredient matches for Cidalin

Mebhydrolin

Mebhydrolin napadisilate (a derivative of Mebhydrolin) is reported as an ingredient of Cidalin in the following countries:

• Israel

International Drug Name Search

Penilente

Penilente may be available in the countries listed below.

Ingredient matches for Penilente

Benzylpenicillin

Benzylpenicillin benzathine (a derivative of Benzylpenicillin) is reported as an ingredient of Penilente in the following countries:

• Egypt


• Ethiopia


• Ghana


• Kenya


• Nigeria


• South Africa


• Sudan


• Tanzania


• Uganda


• Zambia

Benzylpenicillin sodium (a derivative of Benzylpenicillin) is reported as an ingredient of Penilente in the following countries:

• Egypt


• Ghana


• Kenya


• Nigeria


• Sudan


• Tanzania


• Uganda


• Zambia

International Drug Name Search

Coraspin

Coraspin may be available in the countries listed below.

Ingredient matches for Coraspin

Aspirin

Acetylsalicylic Acid is reported as an ingredient of Coraspin in the following countries:

• Turkey

International Drug Name Search

Fluoxetine Generics

Fluoxetine Generics may be available in the countries listed below.

Ingredient matches for Fluoxetine Generics

Fluoxetine

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Fluoxetine Generics in the following countries:

• Greece

International Drug Name Search

Bioflutikazon

Bioflutikazon may be available in the countries listed below.

Ingredient matches for Bioflutikazon

Fluticasone

Fluticasone is reported as an ingredient of Bioflutikazon in the following countries:

• Poland

International Drug Name Search

Leuprorelina

Leuprorelina may be available in the countries listed below.

Ingredient matches for Leuprorelina

Leuprorelin

Leuprorelina (DCIT) is also known as Leuprorelin (Rec.INN)

International Drug Name Search

Glossary

DCIT	Denominazione Comune Italiana
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Magnyl DAK

Magnyl DAK may be available in the countries listed below.

Ingredient matches for Magnyl DAK

Aspirin

Acetylsalicylic Acid is reported as an ingredient of Magnyl DAK in the following countries:

• Denmark

International Drug Name Search

Glygard

Glygard may be available in the countries listed below.

Ingredient matches for Glygard

Gliclazide

Gliclazide is reported as an ingredient of Glygard in the following countries:

• South Africa


• Sri Lanka

International Drug Name Search

Basazyde

Basazyde may be available in the countries listed below.

Ingredient matches for Basazyde

Balsalazide

Balsalazide disodium salt, dihydrate (a derivative of Balsalazide) is reported as an ingredient of Basazyde in the following countries:

• Taiwan

International Drug Name Search

Microgyn

Microgyn may be available in the countries listed below.

Ingredient matches for Microgyn

Ethinylestradiol

Ethinylestradiol is reported as an ingredient of Microgyn in the following countries:

• Denmark

Levonorgestrel

Levonorgestrel is reported as an ingredient of Microgyn in the following countries:

• Denmark

International Drug Name Search

Theo-Dur

In the US, Theo-Dur (theophylline systemic) is a member of the drug class methylxanthines and is used to treat Apnea of Prematurity, Asthma - acute and Asthma - Maintenance.

US matches:

• Theo-Dur

Ingredient matches for Theo-Dur

Theophylline

Theophylline is reported as an ingredient of Theo-Dur in the following countries:

• Denmark


• Greece


• Iceland


• Italy


• Norway


• Spain


• Sweden

International Drug Name Search

Alprax

Alprax may be available in the countries listed below.

Ingredient matches for Alprax

Alprazolam

Alprazolam is reported as an ingredient of Alprax in the following countries:

• Australia


• Bangladesh


• India


• Lithuania

International Drug Name Search

Polyspectran Salbe

Polyspectran Salbe may be available in the countries listed below.

Ingredient matches for Polyspectran Salbe

Bacitracin

Bacitracin is reported as an ingredient of Polyspectran Salbe in the following countries:

• Germany

Neomycin

Neomycin sulfate (a derivative of Neomycin) is reported as an ingredient of Polyspectran Salbe in the following countries:

• Germany

Polymyxin B

Polymyxin B sulfate (a derivative of Polymyxin B) is reported as an ingredient of Polyspectran Salbe in the following countries:

• Germany

International Drug Name Search

Atriance

Atriance may be available in the countries listed below.

UK matches:

• Atriance 5 mg/ml solution for infusion (SPC)

Ingredient matches for Atriance

Nelarabine

Nelarabine is reported as an ingredient of Atriance in the following countries:

• Austria


• Belgium


• Canada


• Denmark


• Finland


• France


• Germany


• Italy


• Luxembourg


• Netherlands


• Norway


• Slovenia


• Spain


• Sweden


• Switzerland


• United Kingdom

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Clozapine Sandoz

Clozapine Sandoz may be available in the countries listed below.

Ingredient matches for Clozapine Sandoz

Clozapine

Clozapine is reported as an ingredient of Clozapine Sandoz in the following countries:

• Belgium


• Estonia


• Latvia


• Lithuania


• Sweden

International Drug Name Search